Clinical trial Recruiting at 1 site Observational Ages 18 and up

Linking a hip-worn smartphone gait sensor with spinal MRI in people with multiple sclerosis

Official title: Individual Gait Pattern and MRI Lesion Load to Quantify Gait Impairment in MS: A Cross Sectional Study.

Run by Nantes University Hospital · NCT05482906 · Data updated 2026-11-12

This project will try whether combining a hip-worn IMU smartphone app and routine spinal MRI can better describe walking changes in adults with multiple sclerosis.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment100 (estimated)
SponsorNantes University Hospital
Academic / other
Locations1 site (Nantes, Loire-Atlantique)
StatusRecruiting
StartedApril 3, 2023
Main results expectedApril 30, 2026
Study endsJune 30, 2026
Registry record updatedMarch 13, 2026
Trial IDNCT05482906 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults over 18 with a diagnosis of multiple sclerosis (EDSS 0–6), followed at Nantes or Rennes University Hospitals, free of relapse for at least 3 months, and scheduled for a spinal MRI are ideal candidates.

Probably not a fit

Patients who require bilateral walking aids, are pregnant, under guardianship, or who decline participation are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational project uses a commercial IMU sensor worn at the right hip (MetaMotionR), a smartphone app, and an algorithm to extract an individual gait pattern (IGP) represented as a quaternion-based rotation curve. Adults with MS (EDSS 0–6) who are followed at Nantes or Rennes University Hospitals and have a spinal MRI planned as part of routine care will perform a walking test while wearing the device. Investigators will compare the smartphone-derived gait curves with routine spinal MRI findings obtained within four months of the walking test to look for common and specific signatures. The goal is to refine noninvasive, easy-to-collect digital markers of gait that can be linked to neuroimaging changes.

Why it matters

Potential benefit: If successful, this approach could provide clinicians with objective, easy-to-collect gait measures that relate to spinal MRI findings and help personalize monitoring and care.

How similar studies have gone: Previous work using IMU-derived individual gait patterns has shown promise for detecting gait changes in MS, but combining those patterns with MRI information is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria :

* Diagnosis of MS based on McDonald criteria (including Relapsing-remitting and progressive MS)
* Over 18 years old /age greater than 18 years
* Patients followed at Nantes university hospital or Rennes university hospital
* Last known EDSS before inclusion ranging from 0 to 6 inclusive/EDSS of 0 to 6 inclusive, prior inclusion
* No relapse within 3 months
* With a Medullar MRI planed as part as usual care
* MRI scan can be performed within a maximum of 4 months after or before the walking test.
* Affiliated person or beneficiary of a social security scheme

Exclusion Criteria :

* Bilateral aid needed to walk
* Women who are pregnant
* Patient having expressed their opposition
* Patient under guardianship or security measure

Where it's running

  • Nantes University Hospital
    Nantes, Loire-Atlantique, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.